Amytrx Therapeutics, Inc.
Amytrx Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-generation anti-inflammatory peptide therapies for chronic inflammatory diseases. Their lead program, AMTX-100, is a first-in-class cell-penetrating peptide that modulates inflammation by targeting importins, with potential applications across various inflammatory, autoimmune, and metabolic diseases. The company emphasizes collaboration, innovation, and advancing therapies with a focus on safety and efficacy.
Industries
Nr. of Employees
small (1-50)
Amytrx Therapeutics, Inc.
40 Burton Hills Boulevard | Suite 260, Nashville, TN 37215
Products
Clinical-stage cell-penetrating anti-inflammatory peptide (lead topical formulation)
A clinical-stage, cell-penetrating peptide therapeutic bioengineered from human protein sequences that modulates inflammation via intracellular inhibition of nuclear transport of pro-inflammatory transcription factors; developed as a topical cream with plans for multiple formulation routes.
Clinical-stage cell-penetrating anti-inflammatory peptide (lead topical formulation)
A clinical-stage, cell-penetrating peptide therapeutic bioengineered from human protein sequences that modulates inflammation via intracellular inhibition of nuclear transport of pro-inflammatory transcription factors; developed as a topical cream with plans for multiple formulation routes.
Services
Establishing research collaborations, licensing agreements, and sponsored projects to apply peptide platform sequences across therapeutic indications.
Sponsorship and operational coordination of early-stage clinical trials, including IND-enabled studies, enrollment, and assessment of safety and exploratory biological endpoints.
Management of chemistry, manufacturing and control (CMC) activities and topical/multi-route formulation development via outsourced manufacturing partners.
Establishing research collaborations, licensing agreements, and sponsored projects to apply peptide platform sequences across therapeutic indications.
Sponsorship and operational coordination of early-stage clinical trials, including IND-enabled studies, enrollment, and assessment of safety and exploratory biological endpoints.
Management of chemistry, manufacturing and control (CMC) activities and topical/multi-route formulation development via outsourced manufacturing partners.
Expertise Areas
- Peptide therapeutics development
- Translational immunology and immune modulation
- Formulation development (topical and multi-route)
- Preclinical safety and animal models
Key Technologies
- Cell-penetrating peptides
- Peptide bioengineering from human protein sequences
- Importin / nuclear transport modulation (NLS decoy)
- Topical cream formulation
News & Updates
A recent study by Vanderbilt investigators with initial support provided by Amytrx Therapeutics demonstrated the molecular control of inflammation in an experimental mouse model of atopic dermatitis.
Research on controlling inflammation in skin cells by targeting nuclear transport mechanisms.
Research on the genomic basis of sepsis in lungs and kidneys.
Presentation of clinical trial data for AMTX-100 in atopic dermatitis.
Research on inflammation control in atopic dermatitis mouse models.
Overview of recent developments in topical treatments for atopic dermatitis.
A recent study by Vanderbilt investigators with initial support provided by Amytrx Therapeutics demonstrated the molecular control of inflammation in an experimental mouse model of atopic dermatitis.
Research on controlling inflammation in skin cells by targeting nuclear transport mechanisms.
Research on the genomic basis of sepsis in lungs and kidneys.
Presentation of clinical trial data for AMTX-100 in atopic dermatitis.
Research on inflammation control in atopic dermatitis mouse models.
Overview of recent developments in topical treatments for atopic dermatitis.